0
0.0
Feb 2, 2024
02/24
by
CNBC
tv
eye 0
favorite 0
quote 0
obesity is top of mind for everyone. >> let's go back to novartis i mentioned my colleague i conductedhat interview this week that reaction was telling because investors were not blown away the stock was down 4% on the day when the results came out. this is coming on from 2023 being a year of restructuring and refocus for novartis why was the investment community under-whelmed? >> the results is a case of expectations being super, super high they delivered operationally in 2023 three beats in a row. expectations were for a flawless guide and quarter. it was still good, but there were a little bit of hiccups one cancer drug missed expec expectations guidance below consensus that is why the stock gave back a bit. >> we saw roche this week guided weaker they saw a miss on the pharma division how is the prospects for roche >> we are describing the company in transitional phase. they are slowing a little with momentum in the key pharma products we will not see more pivotal readouts until later this year or next year investors are stuck in the middle at the moment >> it is a tricky one. novo
obesity is top of mind for everyone. >> let's go back to novartis i mentioned my colleague i conductedhat interview this week that reaction was telling because investors were not blown away the stock was down 4% on the day when the results came out. this is coming on from 2023 being a year of restructuring and refocus for novartis why was the investment community under-whelmed? >> the results is a case of expectations being super, super high they delivered operationally in 2023...
0
0.0
Feb 5, 2024
02/24
by
BLOOMBERG
tv
eye 0
favorite 0
quote 0
we will also take a look at novartis, up more than 3.6%.t agreed to buy three manufacturing plants 411 billion dollars to meet the manufacturing needs. estee lauder is up on most 12% on the day, the biggest surge since 2011 after it says it will cut as many as 3000 physicians as part of a restructuring -- 3000 positions as part of a restructuring plan. we have to talk about the divergence particularly in the magnificent seven stocks. meta is a clear outlier particularly after the gains you've seen more recently while tesla has diverged even more. this is a trend we've slowly seen through 2023 but we are really seeing that become more pronounced. some investors and analyst are saying maybe there should be new members of that magnificent seven. we will talk to ellenhayson at fln putnam. if you think about just how much you see tesla falling away from the back with meta rising in other names getting more love this year, how do you think about the tech giants going into 2024? >> as we look into 2024, we think it will be very much company specif
we will also take a look at novartis, up more than 3.6%.t agreed to buy three manufacturing plants 411 billion dollars to meet the manufacturing needs. estee lauder is up on most 12% on the day, the biggest surge since 2011 after it says it will cut as many as 3000 physicians as part of a restructuring -- 3000 positions as part of a restructuring plan. we have to talk about the divergence particularly in the magnificent seven stocks. meta is a clear outlier particularly after the gains you've...
0
0.0
Feb 27, 2024
02/24
by
KGO
tv
eye 0
favorite 0
quote 0
. >> when the drug was developed by bay area based genentech, partnering with novartis in the stanford trial, it was shown to be safe and effective even in small children. doctors say the treatment doesn't eliminate the allergy. kids still have to be extremely cautious about avoiding snacks with nuts or other foods that they're allergic to, but the injections are able to keep patients safe from accidental reactions. annabelle's mom, victoria, says the extra protection is a relief from the almost constant stress. >> you know, travel, all going to school, going to events, assuring that whatever's on the plate doesn't have of nuts or cross-contamination with nuts. >> and for annabelle, it's a chance to live her active life with confidence. i do competitive dance. >> i, i play softball, i'm a girl scouts. i really like a lot of stuff. >> gloria rodriguez, abc seven news. >> based on the results of the trial, the fda has just officially approved for the drug for treating food allergies. we'll be right back that's the san francisco chronicle endorsing democrat katie porter for senate over al
. >> when the drug was developed by bay area based genentech, partnering with novartis in the stanford trial, it was shown to be safe and effective even in small children. doctors say the treatment doesn't eliminate the allergy. kids still have to be extremely cautious about avoiding snacks with nuts or other foods that they're allergic to, but the injections are able to keep patients safe from accidental reactions. annabelle's mom, victoria, says the extra protection is a relief from the...
0
0.0
Feb 6, 2024
02/24
by
CNBC
tv
eye 0
favorite 0
quote 0
. >>> also in pharma, novartis is set to acquire morphosys for 2.7 billion euro.t will pay cash for the company which it will take private after completion. you see the stock down .30%. morphosys is up 14% on the news. >>> switching to infineon in germany. shares are lower after the chip maker was downgraded. ge german firm posted quarterly net income of 587 million euros. the ceo outlined the issues facing the group. >> i think the market reaction is echoing the current macro challenges we are all witnessing. we have a two tales of the market with auto very strong. we have to confess that is the key driver of the lower guidance for the fiscal year. we have to confess the consumer compute communication markets recovery is delayed and probably that is what the market is looking at currently. >> interesting. >>> sticking with the chip space, nordic semiconductor has a loss of $7 million. the chip maker cited a slowdown in the sector due to headwinds and expects lower revenue between $70 million and $80 million. these two stories highlight that not all chip makers ar
. >>> also in pharma, novartis is set to acquire morphosys for 2.7 billion euro.t will pay cash for the company which it will take private after completion. you see the stock down .30%. morphosys is up 14% on the news. >>> switching to infineon in germany. shares are lower after the chip maker was downgraded. ge german firm posted quarterly net income of 587 million euros. the ceo outlined the issues facing the group. >> i think the market reaction is echoing the current...
0
0.0
Feb 27, 2024
02/24
by
KGO
tv
eye 0
favorite 0
quote 0
. >> when the drug was developed by bay area based genentech, partnering with novartis in the stanfordrial, it was shown to be safe and effective even in small children. doctors say the treatment doesn't eliminate the allergy. kids still have to be extremely cautious about avoiding snacks with nuts or other foods that they're allergic to, but the injections are able to keep patients safe from accidental reactions. annabelle's mom, victoria, says the extra protection is a relief from the almost constant stress. >> you know, travel, all going to school, going to events, assuring that whatever's on the plate doesn't have nuts or cross contamination with nuts. >> and for annabel, it's a chance to live her active life with confidence. >> i do competitive dance. i i play softball, i'm a girl scouts. i really like a lot of stuff. >> gloria rodriguez, abc seven news. >> that's great. and based on the results of the trial, the fda has just officially approved that genentech drug for treating food allergies. >> that is a game changer. >> it really is. >> all right, let's turn our attention now t
. >> when the drug was developed by bay area based genentech, partnering with novartis in the stanfordrial, it was shown to be safe and effective even in small children. doctors say the treatment doesn't eliminate the allergy. kids still have to be extremely cautious about avoiding snacks with nuts or other foods that they're allergic to, but the injections are able to keep patients safe from accidental reactions. annabelle's mom, victoria, says the extra protection is a relief from the...
0
0.0
Feb 5, 2024
02/24
by
CNBC
tv
eye 0
favorite 0
quote 0
blockbuster weight loss drug wegovy, in dallas, we're in pharma, more forces is surging as reports that novartis is in talks to buy the cancer treatment company. the report doesn't include a potential price, but more forces currently has market cap of roughly two billion dollars. shares are having their best day ever, up some 58%, as numbers trades along the flat line. >> it, but we'll be back to shortly. pippa stevens, thank you. we're just getting started here on closing bell. up next, giving out the fed, jpmorgan asset management, gabriela santos is with us. mapping out her rate cut forecast and of course the playbook to. we are live from the new york stock exchange, you are watching closing bell on cnbc. ♪♪ whoo! ♪♪ light work! ♪♪ next victims. ♪♪ you ready for this? ♪pump up the jam pump it up♪ your record label is taking off. but so is your sound engineer. you need to hire. i need indeed. indeed you do. indeed instant match instantly delivers quality candidates matching your job description. visit indeed.com/hire moving forward with node- positive breast cancer is overwhelming. but i never
blockbuster weight loss drug wegovy, in dallas, we're in pharma, more forces is surging as reports that novartis is in talks to buy the cancer treatment company. the report doesn't include a potential price, but more forces currently has market cap of roughly two billion dollars. shares are having their best day ever, up some 58%, as numbers trades along the flat line. >> it, but we'll be back to shortly. pippa stevens, thank you. we're just getting started here on closing bell. up next,...
0
0.0
Feb 27, 2024
02/24
by
KGO
tv
eye 0
favorite 0
quote 0
and effective even in small children, bayer based genentech developed the drug in partnership with novartis. abc seven news spoke with one mother, whose daughter is in the trial, and she says it is relieved some of her constant stress travel, um, going to school, going to events, assuring that, um, whatever's on the plate doesn't have nuts or cross contamination with nuts. while it is not a cure, doctors say it can protect children from dangerous and sometimes life threatening reactions. >> now it's their morning money report. big news for macy's. they're going to start notifying some employees today if their store will close. the company announced overnight it plans to close about 150 locations by the end of 2026. the company says this is part of an effort to keep macy's profitable and stave off a pending takeover bid. it plans to open small versions of bloomingdale's and its chain of cosmetic stores, called bluemercury. there are 15 macy's stores in the bay area. last month, macy's said the bayfair center location in san leandro will close. it's unclear if this morning's announcement will
and effective even in small children, bayer based genentech developed the drug in partnership with novartis. abc seven news spoke with one mother, whose daughter is in the trial, and she says it is relieved some of her constant stress travel, um, going to school, going to events, assuring that, um, whatever's on the plate doesn't have nuts or cross contamination with nuts. while it is not a cure, doctors say it can protect children from dangerous and sometimes life threatening reactions....
0
0.0
Feb 27, 2024
02/24
by
KGO
tv
eye 0
favorite 0
quote 0
the bay area based genentech developed the drug in partnership with novartis.news spoke with one mother, whose daughter is in this trial. she says it has relieved some of her constant stress travel, um, going to school, going to events, assuring that whatever's on the plate doesn't have nuts or cross contamination with nuts. while it is not a cure, doctors say it can protect children from dangerous and sometimes life threatening reactions. >> 536 this morning, frost advisories up in the north bay, our coldest city starting out in the 30s. take that winter jacket with you, but also take the sunglasses for a beautiful afternoon on the way. sunny skies. we're dry. upper 50s to the mid 60s. a quick look at the tahoe forecast today. tomorrow even midday thursday. looking. fine, but do not go up there. friday or saturday. we're tracking heavy snow, blizzard conditions and possible travel. very likely. amanda >> all right. thank you so much drew. new at six security concerns at a san francisco high school after a man is able to sneak inside the girls locker room and f
the bay area based genentech developed the drug in partnership with novartis.news spoke with one mother, whose daughter is in this trial. she says it has relieved some of her constant stress travel, um, going to school, going to events, assuring that whatever's on the plate doesn't have nuts or cross contamination with nuts. while it is not a cure, doctors say it can protect children from dangerous and sometimes life threatening reactions. >> 536 this morning, frost advisories up in the...
0
0.0
Feb 16, 2024
02/24
by
BLOOMBERG
tv
eye 0
favorite 0
quote 0
novartis says it is working on the next generation of obesity drugs after missing the first wave of weightts. the lucrative market has been dominated by competitors. the ceo telling david rubenstein what is on the horizon for the company. >> we are working on the next wave of medicines. i think these glp-1 medicines are very well serviced by current companies. think there is opportunity to improve on them, and it is very early stage, but can we come up with drugs that better preserve muscle, are easier to take, and more infrequently taken? yahaira: the full interview will air on march 6. that is your bloomberg brief. lisa: up next, a looming government shutdown deadline. >> you are not going to get another continuing resolution out of our conference. when we come back the key is going to be, what are the packages put on the floor? lisa: we get to talk about that coming up next. this is bloomberg. ♪ ♪ how am i going to find a doctor when i'm hallucinating? what do you think, fever monster? what about zocdoc? zocdoc? dr. castell has a great bedside manner. so many options. but dr. xichun wil
novartis says it is working on the next generation of obesity drugs after missing the first wave of weightts. the lucrative market has been dominated by competitors. the ceo telling david rubenstein what is on the horizon for the company. >> we are working on the next wave of medicines. i think these glp-1 medicines are very well serviced by current companies. think there is opportunity to improve on them, and it is very early stage, but can we come up with drugs that better preserve...
0
0.0
Feb 19, 2024
02/24
by
BLOOMBERG
tv
eye 0
favorite 0
quote 0
one area where novartis is one of the leaders is rna therapies.wering, we have a medicine that you only have to take twice a year to lower cholesterol 60%. we are working on some of medicines for hypertension, blood pressure, other risk factors for cardiovascular disease. most people do not stay on their drugs. david: in 2023, ai burst onto the scene. everybody is now excited about ai. i was ai affecting your company? >> i think it will take more time than most people expect. productivity areas of ai has -- applications. productivity, we can use it for document generation, not sexy areas. in our sector most uniquely, can you speed up drug r&d? we are working in clinical trials, optimizing clinical trials, but the big bets with county fairs, microsoft, google, if you others to say can you really discover novel drugs without ai? can you optimize drugs more quickly? this is all about a technology called oval fold. there is opportunity here, but you also have to acknowledge we only understand about 5% to 10% of what goes on in the human body. expect a
one area where novartis is one of the leaders is rna therapies.wering, we have a medicine that you only have to take twice a year to lower cholesterol 60%. we are working on some of medicines for hypertension, blood pressure, other risk factors for cardiovascular disease. most people do not stay on their drugs. david: in 2023, ai burst onto the scene. everybody is now excited about ai. i was ai affecting your company? >> i think it will take more time than most people expect. productivity...